Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.
Dovedi, Simon J
West, Catharine M L
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester
MetadataShow full item record
AbstractPre-treatment lymphocytopaenia may result from cytokines secreted by the tumour microenvironment in association with aggressive tumour biology. We sought to establish the prognostic significance of lymphocytopaenia in muscle invasive and advanced bladder cancer.
CitationPre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. 2015: Ann Oncol
JournalAnnals of Oncology